Despite its relatively recent approval for treatment of HER2+ breast cancer, several mechanisms of resistance to neratinib have been proposed, including decreased pro-apoptotic BCL2 family member expression, and increased cytochrome P450 (CYP) 3A4 activity [71,118]. This evidence concerns the gene ERBB2 and breast carcinoma.